AI Summary
The OCEANIC-AF trial of factor XI inhibitor asundexian has been stopped early due to it being less effective than apixaban in preventing stroke and systemic embolism in AF patients.
The phase 3 OCEANIC-AF trial of the factor XI inhibitor asundexian (Bayer) has been stopped early owing to inferior efficacy vs apixaban in preventing stroke and systemic embolism in patients with AF.
Medscape Medical News